Protagenic Closes $1.5M Initial Tranche of Up to $5M Private Placement at $0.61/Share
PTIX has more than doubled off its 52-week low of $0.128 on light trading volume (0.1× avg).
Summary
Protagenic closed the first $1.5 million of a private placement at $0.61 per share, issuing 2.46 million shares and 4.92 million warrants, with up to $5 million total available. The money funds the PT00114 IND and first U.S. trial, but the warrants carry anti-dilution ratchets and expire around the tenth-patient dosing milestone.
Key Events · Financing and Capital Events · PTIX
-
Initial Closing: $1.5M at $0.61/Share
At $0.61 per share — 90% of the 30-day VWAP — the initial closing issued 2,459,014 shares plus 2,459,014 Series A and 2,459,014 Series B warrants, for gross proceeds of approximately $1.5 million before fees.
-
Up to $5M Total Available
The maximum offering is $3,000,000, which the company may increase at its discretion to $5,000,000, with additional closings permitted until the earlier of December 31, 2026 and full subscription.
-
Warrant Ratchets and Early Expiry
Series A warrants strike $0.67 and Series B $0.73, both cash-exercise only, with full-ratchet anti-dilution on later share sales below the strike; all warrants expire 30 days after public disclosure of dosing the tenth patient in the PT00114 Phase 1/2a trial.
-
Placement Agent Economics
Brookline Capital Markets receives a 7.0% cash fee, a 1.0% expense allowance, up to $75,000 of reimbursed expenses, and placement agent warrants equal to 7.0% of the common warrants issued to investors.
Analysis · PTIX · Life Sciences
Protagenic raised $1.5 million in an initial closing of a private placement priced at $0.61 per share — 90% of the trailing 30-day VWAP — with up to $3.5 million more available if two series of milestone-linked warrants are exercised. The cash matters because the last 10-Q showed $565,985 of cash and substantial doubt about going concern; this tranche plus the warrant overhang is what funds the IND submission and the first U.S. Phase 1/2a trial in generalized anxiety disorder. The cost is dilution: 2,459,014 shares plus 4,918,028 warrants were issued at the initial closing, and the Series A and B warrants carry full-ratchet anti-dilution on later share sales below their exercise prices, so future financings could add more shares than the headline count suggests. The warrants also expire early — 30 days after public disclosure of dosing the tenth patient in the Phase 1/2a trial — which ties the warrant holders' window to the company's own clinical timeline.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTIX was trading at $0.46 on OTC in the Life Sciences sector, with a market capitalization of approximately $828.2K. The 52-week trading range was $0.13 to $3.77. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.